European Mediscience Awards
Thursday 13 June 2024, Hotel InterContinental, London W1
Nominations are open
CLOSING DATE: THURSDAY 4 APRIL 2024
About
About the Awards
Showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors
The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector.
Each year sees the attendance of over 500 quoted and private UK and European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. The event is sold out from one year to the next.
The European Mediscience Awards 2024 will take place on Thursday 13 June at the Hotel InterContinental, London, W1.
*with the exception of 2020 when we were unable to hold a live event due to COVID-19, but instead held a successful digital campaign.
Contact us
Sponsors
HSBC Innovation Banking provides commercial banking services, expertise and insights to the technology, life science and healthcare, private equity and venture capital industries. HSBC Innovation Banking is a subsidiary of HSBC Group, benefiting from its stability, strong credit rating and international reach to help fuel its growth.
Mainline sponsor:
HSBC Innovation Banking provides commercial banking services, expertise and insights to the technology, life science and healthcare, private equity and venture capital industries. HSBC Innovation Banking is a subsidiary of HSBC Group, benefiting from its stability, strong credit rating and international reach to help fuel its growth.
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges.
We work in partnership with our clients to translate complex healthcare situations into meaningful communications programmes that deliver sustained results, inspire action and build value. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information, please see
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges.
We work in partnership with our clients to translate complex healthcare situations into meaningful communications programmes that deliver sustained results, inspire action and build value. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information, please see
FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. Our large team of life sciences and healthcare specialists has the breadth and depth of experience, in pharmaceuticals, biotech, medical devices, digital health and healthcare services, to help you ensure that the right message reaches the right audience at the right time.
We take a holistic view, helping clients, ranging from top-10 global pharmaceutical and medical device companies to small start-ups, to develop and defend their reputations; seek to attract and retain the best talent; navigate and inform health and policy agendas; and steady themselves for moments of change or periods of growth.
Whether you need support for capital markets transactions or fundraisings, digital and social media strategies to meet growing sector demand; internal change communication after transactions; market preparedness and product launch communications; crisis preparedness or response, clinical and regulatory milestone communications; corporate messaging or public affairs support, FTI has the expertise and capabilities to help you.
www.fticonsulting-emea.com/industries/healthcare-and-life-sciences
FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. Our large team of life sciences and healthcare specialists has the breadth and depth of experience, in pharmaceuticals, biotech, medical devices, digital health and healthcare services, to help you ensure that the right message reaches the right audience at the right time.
We take a holistic view, helping clients, ranging from top-10 global pharmaceutical and medical device companies to small start-ups, to develop and defend their reputations; seek to attract and retain the best talent; navigate and inform health and policy agendas; and steady themselves for moments of change or periods of growth.
Whether you need support for capital markets transactions or fundraisings, digital and social media strategies to meet growing sector demand; internal change communication after transactions; market preparedness and product launch communications; crisis preparedness or response, clinical and regulatory milestone communications; corporate messaging or public affairs support, FTI has the expertise and capabilities to help you.
www.fticonsulting-emea.com/industries/healthcare-and-life-sciences
MEDISTRAVA Consulting is an international healthcare advisory and strategic communications group, partnering with innovative biopharma companies and leading life science VCs.
We are a cross-functional group of experts offering best-in-class solutions designed to maximise corporate and asset value along the full development journey from discovery to product launch and beyond, including.
- Strategic Corporate, Scientific/Clinical and Investor Communications
- Equity Story Development
- Media Relations and Reputation Management
- Commercial Opportunity Assessment, Analytics & Development Strategy
- Scientific Narrative Development and Evidence Generation/Endorsement
- Market Access, Pricing & Health Economics and Outcomes Research
We are part of Inizio, a global commercialisation platform that unlocks, activates and optimises value for pharma and biopharma at each pivotal moment.
MEDISTRAVA Consulting is an international healthcare advisory and strategic communications group, partnering with innovative biopharma companies and leading life science VCs.
We are a cross-functional group of experts offering best-in-class solutions designed to maximise corporate and asset value along the full development journey from discovery to product launch and beyond, including.
- Strategic Corporate, Scientific/Clinical and Investor Communications
- Equity Story Development
- Media Relations and Reputation Management
- Commercial Opportunity Assessment, Analytics & Development Strategy
- Scientific Narrative Development and Evidence Generation/Endorsement
- Market Access, Pricing & Health Economics and Outcomes Research
We are part of Inizio, a global commercialisation platform that unlocks, activates and optimises value for pharma and biopharma at each pivotal moment.
SP Angel provides broking and corporate finance advisory services to over 60 companies across the Healthcare, Technology and Natural Resources sectors. Our Healthcare Team has a proven track record in raising funds for both private and quoted companies.
SP Angel provides broking and corporate finance advisory services to over 60 companies across the Healthcare, Technology and Natural Resources sectors. Our Healthcare Team has a proven track record in raising funds for both private and quoted companies.
Panmure Gordon, an innovative and forward-thinking investment bank, helps fast-growing corporate and institutional clients achieve their ambitions and has offices in London, Leeds and New York. It provides a full range of services including Corporate Broking, Corporate Advisory, Capital Raising, Investor Relations, Research, Sales, Sales Trading and Market Making.
Panmure Gordon, an innovative and forward-thinking investment bank, helps fast-growing corporate and institutional clients achieve their ambitions and has offices in London, Leeds and New York. It provides a full range of services including Corporate Broking, Corporate Advisory, Capital Raising, Investor Relations, Research, Sales, Sales Trading and Market Making.
Cavendish is a champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.
Cavendish has offices in London and Edinburgh and has a global reach through its membership of Oaklins.
supported by:
Cavendish is a champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.
Cavendish has offices in London and Edinburgh and has a global reach through its membership of Oaklins.
Awards
covering the period 1 April 2023 to 31 March 2024
Nominations are open
Nominations overview
Click on each award to view more information
BEST COMMUNICATION AWARD
Sponsored by:
BEST COMMUNICATION AWARD
Sponsored by
Criteria
Successful communication is vital to the development of mediscience companies.
Newsflow, both good and bad, can have a significant effect on share prices, and the winner of this award will have demonstrated its ability to successfully communicate its investment message to its target audience.
2023 Winner
2023 Shortlist
- C4X Discovery Holdings plc
- Convatec Group plc
- Ergomed plc
- Ion Beam Applications SA
- Sectra AB
- Uniphar plc
BREAKTHROUGH OF THE YEAR AWARD
Sponsored by:
BREAKTHROUGH OF THE YEAR AWARD
Sponsored by
Criteria
The winner of this award will be the company or organisation which has achieved the most significant breakthrough during the period 1 April 2023 to 31 March 2024.
This breakthrough could be a new discovery, departure or breakthrough in technology, a significant positive change in its financial position, or other breakthrough which has added significantly to the company’s or organisation’s fortunes.
2023 Winner
2023 Shortlist
- argenx
- Calliditas Therapeutics AB
- Destiny Pharma plc
- Kooth plc
- Pharming Group N.V.
- Polarean Imaging plc
BEST TECHNOLOGY AWARD
BEST TECHNOLOGY AWARD
Criteria
The technology that lies at the heart of this award does not have to be proven, but it will, in the eyes of the Voting Panel, be innovative, well funded, and capable of significant commercial success. The technology concerned could have been developed within the organisation or acquired.
2023 Winner
2023 Shortlist
- ANGLE plc
- Diaceutics plc
- hVIVO plc
- Newron Pharmaceuticals SpA
- Oxford BioDynamics plc
- Polarean Imaging plc
- Sequana Medical NV
THE EMERGING STAR AWARD
Sponsored by:
THE EMERGING STAR AWARD
Sponsored by
Criteria
The Emerging Star will be a private or young public mediscience company that has demonstrable credibility in terms of business model/strategy, management team and financing. The winner's focus on innovation will also be key, with its technology/IP capable of significant market impact or disruption.
The Emerging Star may not be able to demonstrate too much of a track record, but it will be judged against the demanding criteria that exist for its quoted company peers. The purpose of this award is to broaden knowledge, exchange ideas and help private businesses understand what could be required of them in the quoted company universe.
2023 Winner
2023 Shortlist
- Amphista Therapeutics Ltd
- Artios Pharma Ltd
- CDR-Life Inc.
- OMass Therapeutics Ltd
- Quell Therapeutics Ltd
- Smart Reporting GmbH
- SNIPR Biome
- Synaffix BV
MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD
MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD
Criteria
This award recognises the importance of clear and concise commentary on the sector. It could be awarded to a journalist, a columnist, a specialist website or a team that is dedicated to providing sharp, perceptive and penetrating commentary about the sector.
In-depth knowledge of the sector is a given; the Voting Panel will be looking for excellence in the way that knowledge is communicated to the wider audience.
2023 Winner
2023 Shortlist
- John Carroll/Endpoints
- Jim Cornall/Labiotech
- Fierce Biotech Team
- Nuala Moran/BioWorld
- Alex Ralph/The Times
- Melanie Senior
CAPITAL MARKET TRANSACTION OF THE YEAR AWARD
Sponsored by:
CAPITAL MARKET TRANSACTION OF THE YEAR AWARD
Sponsored by
Criteria
This award recognises a significant capital market transaction during our period under review. The capital market transaction could be an IPO or a follow-on financing; it would be significant in scope and transformational in nature and would materially enhance the prospects for the business in the short, medium and long term.
In deciding the shortlist and eventual winner, the Voting Panel will take into account the amount raised, stock price performance and the quality of the share register.
2023 Winner
2023 Shortlist
- Abivax SA
- BenevolentAI SA
- BioInvent International AB
- GSK plc
- Novozymes A/S
- Valneva SE
MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD
Sponsored by:
MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD
Sponsored by
Criteria
The winner of this award could be an individual, a company, a government department, research council, etc. who has made the single, biggest, most significant contribution to the sector. Difficult to define, but the Voting Panel will be aware of, and make allowances for, this fact.
2023 Winner
UK BioIndustry Association (BIA)
2023 Shortlist
- Dr Melanie Lee CBE/LifeArc
- Anne Marden
- Novo Nordisk Foundation
- Jane Osbourn OBE/Alchemab Therapeutics Ltd
- Pascal Soriot/AstraZeneca plc
- UK BioIndustry Association (BIA)
CHIEF EXECUTIVE OF THE YEAR AWARD
Sponsored by:
CHIEF EXECUTIVE OF THE YEAR AWARD
Sponsored by
Criteria
The winner will be an individual who has demonstrated exceptional leadership qualities during the year under review. The creation of shareholder value through drive, vision and flair in taking his or her business forward are the qualities the Voting Panel is looking for. The winner will also have recognised the importance of developing a management team and workforce in supporting corporate success.
2023 Winner
Sijmen de Vries/Pharming Group N.V.
2023 Shortlist
- Yamin Khan/hVIVO plc
- Gunilla Osswald/Bioarctic AB
- Miroslav Reljanovic/Ergomed plc
- Adam Steensberg/Zealand Pharma A/S
- David Veitch/Basilea Pharmaceutica AG
- Sijmen de Vries/Pharming Group N.V.
COMPANY OF THE YEAR AWARD
Sponsored by:
COMPANY OF THE YEAR AWARD
Sponsored by
Criteria
The Company of the Year will already have gained recognition by analysts and investors.
It will be a well managed, soundly financed growth business with a well defined strategy to deliver its key financial, ethical and social ambitions. Put simply, the Voting Panel are not necessarily looking for the biggest, but they are looking for the best.
2023 Winner
2023 Shortlist
- argenx
- Ergomed plc
- Formycon AG
- hVIVO plc
- Novo Nordisk A/S
- Pharming Group N.V.
Voting panel
Meeting date: Thursday 2 May 2024
Ian Restall
Ford Sinclair Ltd
(Voting panel Chairman)
Mette Kirstine Agger
Esrum Biotech
Renée Aguiar-Lucander
Calliditas Therapeutics AB
Lisa Anson
Redx Pharma Plc
Hubert Birner
TVM Capital
Tracy Cheung
ICR Consilium
Victoria Darbyshire
JP Morgan
John A. Dawson
Chris Donnellan
Cavendish
Liam Gascoigne-Cohen
SP Angel
Stefan Hamill
Hamill Life Sciences Ltd
Anne Hennecke
MC Services AG
Max Herrmann
Stifel
Ulrich Kinzel
goetzpartners Securities Limited
Tara Raveendran
Polar Capital
Craig Richardson
IP Group plc
Nick Rodgers
SEHTA
Julie Simmonds
Panmure Gordon
Tim Stamper
FTI Consulting
Mark Swallow
MEDiSTRAVA Consulting
Ian Restall
Ford Sinclair Ltd(Voting panel Chairman)
Mette Kirstine Agger
Esrum Biotech
Renée Aguiar-Lucander
Calliditas Therapeutics AB
Lisa Anson
Redx Pharma Plc
Hubert Birner
TVM Capital
Tracy Cheung
ICR Consilium
Victoria Darbyshire
JP Morgan
John A. Dawson
Chris Donnellan
Cavendish
Liam Gascoigne-Cohen
SP Angel
Stefan Hamill
Hamill Life Sciences Ltd
Anne Hennecke
MC Services AG
Max Herrmann
Stifel
Ulrich Kinzel
goetzpartners Securities Limited
Tara Raveendran
Polar Capital
Craig Richardson
IP Group plc
Nick Rodgers
SEHTA
Julie Simmonds
Panmure Gordon
Tim Stamper
FTI Consulting
Mark Swallow
MEDiSTRAVA Consulting
Ian Restall
Ford Sinclair Ltd(Voting panel Chairman)
Mette Kirstine Agger
Esrum Biotech
Renée Aguiar-Lucander
Calliditas Therapeutics AB
Lisa Anson
Redx Pharma Plc
Hubert Birner
TVM Capital
Tracy Cheung
ICR Consilium
Victoria Darbyshire
JP Morgan
John A. Dawson
Chris Donnellan
Cavendish
Liam Gascoigne-Cohen
SP Angel
Stefan Hamill
Hamill Life Sciences Ltd
Anne Hennecke
MC Services AG
Max Herrmann
Stifel
Ulrich Kinzel
goetzpartners Securities Limited
Tara Raveendran
Polar Capital
Craig Richardson
IP Group plc
Nick Rodgers
SEHTA
Julie Simmonds
Panmure Gordon
Tim Stamper
FTI Consulting
Mark Swallow
MEDiSTRAVA Consulting
Ian Restall
Ford Sinclair Ltd
(Voting panel Chairman)
Ian is non-voting Chairman of the Voting Panel.
He is a Director of Ford Sinclair Ltd., Chairman of Design Portfolio Marketing Services Ltd. and a member of the Investor Relations Society.
Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding Design Portfolio in 1991, he has been active in helping many companies with their investor communication and corporate reporting requirements.
Mette Kirstine Agger
Esrum Biotech
Mette has broad international experience within biotech and life sciences both as an investor, as a board member, and operationally, covering business development and licensing, management and financing.
Mette has been appointed to numerous board positions in both private and public companies in Europe and the US. She currently has six board positions in the US and Europe and work as strategic advisor for several companies and initiatives.
Mette previously founded and managed Lundbeckfonden Ventures, completing around 40 European and US investments over a 12 year period, and was part of the management at the Lundbeck Foundation. Before that, she was co-founder and CEO of 7TM Pharma A/S. She started her biotech career as part of the management team of NeuroSearch A/S, responsible for business development and licensing.
Mette started as a patent agent and, over the years, has co-founded several biotech companies. Mette graduated as a biologist from the University of Copenhagen and has an MBA from Henley Business School.
Renée Aguiar-Lucander
Calliditas Therapeutics AB
Renée has been CEO of Calliditas Therapeutics AB since 2017 and previously spent 12 years as an investor in Life Sciences. She was a Partner and COO of Omega Funds prior to which she served as a Partner in the Venture Capital group 3i Group plc in London where she was responsible for managing its publicly quoted assets and European legacy healthcare portfolio. Prior to this, she was a European Group Head and MD in investment banking and has over twelve years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on M&A and raising private and public capital for growth companies in both Europe and the US. Prior to investment banking, Renée worked for five years in European sales and marketing for a financial services-focused software business. Renée has a BA in Finance from Stockholm School of Economics and an MBA from INSEAD. She has significant Board experience from both private and public US and European Board work.
Lisa Anson
Redx Pharma Plc
Lisa Anson is an experienced leader in the global biotech and pharmaceutical sector. As CEO of Redx Pharma since 2018, she has led the transformation of Redx into a significant UK-based clinical-stage biotechnology company focused on fibrotic disease and cancer. Under her stewardship the Company has grown significantly, delivering five drug candidates to the clinical stage of development and establishing a growing pipeline of preclinical assets. During this time, the Company has also secured major partnership deals with large and speciality pharma and secured a series of financings with a range of blue-chip life science focused investors.
Hubert Birner
TVM Capital
Dr. Hubert Birner a Managing Partner of TVM Capital and responsible for the company’s worldwide venture capital strategy for life sciences. He has been with TVM since October 2000. Hubert has had one of the longest active careers in European Venture Capital and has successfully managed/overseen more than 50 investments for TVM. In total, he is overseeing all portfolio investments from 4 TVM funds currently.
He currently serves as Chairman of the Board of AL-S Pharma AG (Zurich, Switzerland), leon-nanodrugs (Munich, Germany) and Spepharm Holdings BV (Amsterdam, the Netherlands), he is also a Supervisory Board Member of Centogene AG (NASDAQ).
For many years, he has been the Chairman/Vice Chairman of the Board of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany, XETRA) which were both acquired by Bayer HealthCare AG and Shire Ltd. as the largest acquisitions in the history of Germany biotechnology. It is also noteworthy that his investments in Horizon Therapeutics and Evotec triggered their transformation into multi-billion-dollar public companies today.
Hubert has also successfully designed and implemented a new “asset centric” project financing investment model for biotechnology/early pharmaceutical companies in close cooperation with Eli Lilly & Company.
Prior to his tenure at TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany for Zeneca Agrochemicals, headquartered in London, UK. In this context, Hubert did manage his first biotechnology investments. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.
Hubert also holds an MBA from Harvard Business School.
Tracy Cheung
ICR Consilium
Tracy has more than 25 years of communications and leadership experience, working with diverse stakeholders and senior executives in healthcare, across a range of disciplines including corporate communications, media relations, investor relations, issues and crisis management, employee engagement, change management, public affairs and marketing communications.
Prior to joining Consilium in 2022, Tracy was Chief Communications Officer at COMPASS Pathways, a Nasdaq-listed mental health care company, where she developed and led communications through a number of financing rounds, including IPO, and several clinical data milestones.
Tracy began her career in communications consultancy, working at Rowland Sallingbury Casey and Brunswick. She has since led in-house communications teams in healthcare and life sciences organisations including Amersham International, GE Healthcare Medical Diagnostics, Essentia (part of Guy’s and St Thomas’ NHS Foundation Trust), and COMPASS Pathways. She has worked in the UK and the US, and has a BSc in Natural Sciences from Durham University.
Victoria Darbyshire
JP Morgan
Victoria joined J.P. Morgan Asset Management in the European Research team covering the healthcare sector over fifteen years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.
John A. Dawson
John A. Dawson, CBE, is a highly experienced and globally respected figure in the healthcare sector.
Most recently, he was Chief Executive Officer of Oxford Biomedica where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, and delivered multiple high value partnerships. The company successfully manufactured the life-saving Oxford/AstraZeneca COVID-19 vaccine in early 2021.
Under John’s leadership, Oxford Biomedica’s success resulted in it entering the FTSE 250 index in 2020. John was subsequently awarded a CBE for services to UK life science in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine.
Prior to Oxford Biomedica, John held various senior executive roles including at Cephalon, Inc. where for most of his tenure he was Managing Director for Europe.
Prior to this, he served as the Financial Director for Serono UK. Mr. Dawson is a Chartered Accountant and holds a BSc in Mathematics from Swansea University.
John is a non-executive director at Ergomed, which provides specialized services to the pharmaceutical industry, Chinese Speciality Pharma Ltd., which brings innovative specialty and rare disease products to China, and Norgine, a leading European specialist pharmaceutical company that has been bringing transformative products to patients for over a century.
Chris Donnellan
Cavendish
Chris has worked as an equity research analyst focused on the healthcare sector for over 20 years, covering pharmaceuticals, medical technology and services within the industry.
Over his career, Chris has worked for both Buy and Sell side businesses, including AXA Investment Management, Dresdner Kleinwort and Evolution Securities. He joined Cenkos (now Cavendish) to cover small-cap Healthcare in 2016.
Prior to moving into the City, Chris completed a degree in Biochemistry and PhD in Nutrition.
Liam Gascoigne-Cohen
SP Angel
Liam joined the team at SP Angel in 2019 where he helped set up the healthcare franchise for the firm. Prior to SP Angel he worked at Northland Capital Partners covering small and mid-cap healthcare companies.
Liam holds BSc and MSc degrees in Biological Sciences from the University of Bristol and Imperial College London.
Stefan Hamill
Hamill Life Sciences Ltd
Stef runs an independent advisory business that enables clients including established life science companies, start-ups and investors in the life sciences ecosystem to formulate their strategies, raise finance and fulfil their potential. Previously, he was a top ranked life sciences analyst in London where he built two #1 franchises that dominated UK life sciences investment banking for over ten years and helped advise, finance, and build some of the most successful companies in the UK sector, including billion-dollar-plus successes such as Abcam, Oxford Nanopore and Syncona.
Anne Hennecke
MC Services AG
Anne has been Managing Partner of MC Services since 2011 and has over 20 years of experience in Financial and Strategic Communications. She was responsible for setting up the MC Services office in Düsseldorf and building the team and operations there. Prior to that, she held senior management positions in international pharma and biotech companies. She headed the Investor Relations and Corporate Communications department of Evotec AG for 10 years and was a member of the company’s Executive Committee. Previously, she was responsible for Investor Relations and Corporate Communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and Nasdaq, multiple M&A programs and major financial transactions. Anne is a pharmacist and marketing expert by training. Her sector expertise includes pharma and life sciences with experience in all major indication areas.
Max Herrmann
Stifel
Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to joining Stifel, Max was Chief Financial Officer of Silence Therapeutics plc. He possesses more than 25 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks. He has also been involved in raising over $1bn for biotech companies.
Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Accountant with Arthur Andersen.
Ulrich Kinzel
goetzpartners Securities Limited
Uli is a Managing Director at goetzpartners. He is responsible for the Industry Group Healthcare. He is a founding partner of Code Securities Limited, a specialist life science investment bank which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013. As Director, Corporate Finance, Ulrich Kinzel was instrumental for building the continental European M&A and Equity Capital Markets business. He was previously a Director of WestLB Panmure’s Life Science Team. He has advised leading international live science companies in more than 60 successful M&A and ECM transactions, including cross-border European, Asian and US public and private takeovers as well as IPOs and secondary offerings on all major European Stock Exchanges. He holds a master’s degree in Business Administration from Munich University.
Tara Raveendran
Polar Capital
Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She is currently working at Polar Capital, which she joined in September 2021, as a consultant focused on independent research for the team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital.
Previously Tara spent over 15 years working in equity research, specialising in European pharmaceuticals, biotechnology and medtech at Lehman Brothers and Jefferies. She has also worked with a number of healthcare-focused startups through her life sciences consultancy, SSquared Consulting, most recently working with the UK government’s Vaccine Taskforce.
Craig Richardson
IP Group plc
Craig is a Partner in IP Group’s Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome, followed by a series of business development roles in UK biotech. He was then part of the founding management team of an in vitro diagnostics company before moving into venture capital investment with Inventages, a life science focused VC fund. He subsequently worked for Fusion IP plc, a specialist investor in university spin-out companies, before joining IP Group in 2014.
Craig has a first-class honours degree in Pharmacy from Cardiff University and a PhD from the School of Pharmacy, University of Nottingham. He also holds an MBA with Distinction from the University of Warwick where he was awarded a Sainsbury Management Fellowship from the Royal Academy of Engineering.
Nick Rodgers
SEHTA
Nick is an experienced Non-executive Director and Chairman with a background as a successful corporate financier. He has considerable experience of businesses in the Healthcare, Medical, Biotechnology, Environmental and Technology sectors. Nick is chairman of SEHTA, one of the largest health technology networking organisations in the UK. He is also a non executive director of Cambridge Cognition Holdings plc. In 2021 he helped sell Alcuris, an emerging Telecare and Telehealth business to Access Group. Until 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company and, through Ipso Ventures, he helped found Therakind, a successful developer of paediatric medicines.
Julie Simmonds
Panmure Gordon
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 20 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.
Tim Stamper
FTI Consulting
Tim is a Director at FTI Consulting and a Life Sciences and Healthcare specialist within the company’s strategic communications segment. Tim focuses on building and protecting the reputations of biotech, pharma, medtech and healthcare companies through corporate, financial and brand communications. He works with a range of private and listed clients across the industry as they navigate rapidly changing environments, communicate key milestones, prepare for crises, and engage with capital markets.
Mark Swallow
MEDiSTRAVA Consulting
Mark has 25+ years of experience in the life sciences sector, spent in communications, journalism and publishing. With 20+ years of agency experience, Mark provides advice and manages communication programs for private and public companies, and specialist VCs. He also has six years of experience as an Editor for biotech business publications and leading peer-reviewed journal. Mark holds a PhD in Molecular Biology from the University of London.
The event
Sponsorship
Sponsorship opportunities sometimes become available, including sponsorship of an individual award, sponsorship of the official drinks reception or sponsorship of the menu. Sponsorship opportunities are, by their very nature, limited. Costs and availability on request.
Hosting a table
Reservations are available for tables of ten people. Numbers are strictly limited and reservations are taken on a first come, first served basis.
Advertising
Advertising in the digital brochure is welcomed and enables your key messages to reach a highly targeted audience. The digital event brochure is available to download on the night and contains details of the all nominees, the programme for the night and the menu. Uniquely, it also contains the names of all attendees, in alphabetical and table order. Thus it is widely used as a reference post event for up to a year afterwards.
Bespoke sponsorship opportunities
We offer a range of bespoke sponsorship packages, tailor made to suit your marketing objectives and budget. Further information on request.
Enquiries
For all enquiries relating to the European Mediscience Awards, please do get in touch with jo.thomas@ford-sinclair.co.uk.
Key details for guests
Date
Thursday 13 June 2024
Venue
Ballroom, Hotel InterContinental
One Hamilton Place
Park Lane
London W1J 7QY
Start time
6.00 p.m. – Drinks reception
7.30 p.m. – Dinner
9.15 p.m. – Awards
9.45 p.m. – After-dinner entertainment
12.00 midnight – Carriages
Dress code
Black Tie
Charity collection
A charity collection will be taken up during the course of the evening and the European Mediscience Awards team will be available throughout to accept contactless donations. Thank you in advance for your generosity.
Accommodation
Hotel InterContinental
Exclusive rates for bedrooms may be available for guests attending the event and further information will be available in due course.
Location
Latest media
Charity
A charity collection was held at the European Mediscience Awards 2023 in respect of two charities: bccs and Young Lives vs Cancer. The total amount raised which was split equally between these two charities was:
£10,832.24
bccs provides highly professional and well‑supported Social Workers and Counsellors to help children and young people who are in need.
bccs works in the East End of London and Essex with children, young people and their families and schools to help them overcome emotional difficulties, behavioural problems and their root causes. The prime focus of the work is to provide an early intervention service to enable them to address difficulties that may be impeding their educational, social and emotional development.
When a child is diagnosed with cancer it threatens everything, for them and their family.
At a time when they should be busy being children, enjoying the rollercoaster teenage years or finding their feet at Uni, life becomes full of fear. Families being torn apart, of overwhelming money worries, mental health stretched to breaking point, of having nowhere to turn, no one to talk to.
At Young Lives vs Cancer we get that and we do everything in our power so no family stands alone to cancer.
We know everyone’s different, so we work hard to make sure each family has what they need to get through.